WO2015111085A3 - Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof - Google Patents

Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof Download PDF

Info

Publication number
WO2015111085A3
WO2015111085A3 PCT/IN2015/000052 IN2015000052W WO2015111085A3 WO 2015111085 A3 WO2015111085 A3 WO 2015111085A3 IN 2015000052 W IN2015000052 W IN 2015000052W WO 2015111085 A3 WO2015111085 A3 WO 2015111085A3
Authority
WO
WIPO (PCT)
Prior art keywords
eltrombopag
processes
preparation
pharmaceutically acceptable
acceptable salts
Prior art date
Application number
PCT/IN2015/000052
Other languages
French (fr)
Other versions
WO2015111085A2 (en
WO2015111085A8 (en
Inventor
Sanjay Jagdish Desai
Shri Prakash Dhar Dwivedi
Jayprakash Ajitsingh PARIHAR
Mahesh Laljibhai Rupapara
Dharmendra Mohanbhai KESHAVALA
Original Assignee
Cadila Healthcare Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Limited filed Critical Cadila Healthcare Limited
Publication of WO2015111085A2 publication Critical patent/WO2015111085A2/en
Publication of WO2015111085A8 publication Critical patent/WO2015111085A8/en
Publication of WO2015111085A3 publication Critical patent/WO2015111085A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06—Preparation of nitro compounds
    • C07C201/08—Preparation of nitro compounds by substitution of hydrogen atoms by nitro groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06—Preparation of nitro compounds
    • C07C201/12—Preparation of nitro compounds by reactions not involving the formation of nitro groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/04—Formation of amino groups in compounds containing carboxyl groups

Abstract

The present invention provides the processes for the preparation of eltrombopag of Formula (I) or its pharmaceutically acceptable salts. The invention also provides crystalline forms of eltrombopag.
PCT/IN2015/000052 2014-01-27 2015-01-27 Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof WO2015111085A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN293MU2014 2014-01-27
IN293/MUM/2014 2014-01-27
IN1946/MUM/2014 2014-06-17
IN1946MU2014 2014-06-17
IN3073MU2014 2014-09-25
IN3073/MUM/2014 2014-09-25

Publications (3)

Publication Number Publication Date
WO2015111085A2 WO2015111085A2 (en) 2015-07-30
WO2015111085A8 WO2015111085A8 (en) 2015-09-03
WO2015111085A3 true WO2015111085A3 (en) 2015-11-12

Family

ID=53059376

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2015/000052 WO2015111085A2 (en) 2014-01-27 2015-01-27 Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof

Country Status (1)

Country Link
WO (1) WO2015111085A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10336706B2 (en) * 2014-09-05 2019-07-02 Hetero Research Foundation Crystalline form of Eltrombopag free acid
CN106146330B (en) * 2015-04-21 2018-04-06 江苏威凯尔医药科技有限公司 A kind of method for preparing eltrombopag olamine intermediate
US11161821B2 (en) * 2018-06-01 2021-11-02 Aurobindo Pharma Ltd. Process for the preparation of Eltrombopag olamine and its intermediates
CN114072386A (en) * 2019-07-04 2022-02-18 F.I.S.-菲博利佳意大利合成面料股份公司 Improved process for the preparation of key intermediates for the synthesis of eltrombopag or salts thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001089457A2 (en) * 2000-05-25 2001-11-29 Smithkline Beecham Corporation Thrombopoietin mimetics
EP2236500A1 (en) * 2008-01-10 2010-10-06 Jiangsu Hengrui Medicine Co., Ltd. Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof
WO2010114943A1 (en) * 2009-04-01 2010-10-07 Pliva Hrvatska D.O.O. Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof
WO2014177517A1 (en) * 2013-04-29 2014-11-06 Esteve Química, S.A. Preparation process of an agonist of the thrombopoietin receptor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI280128B (en) 2002-05-22 2007-05-01 Smithkline Beecham Corp 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
JP4562523B2 (en) 2002-06-06 2010-10-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Thrombopoietin mimetic

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001089457A2 (en) * 2000-05-25 2001-11-29 Smithkline Beecham Corporation Thrombopoietin mimetics
EP2236500A1 (en) * 2008-01-10 2010-10-06 Jiangsu Hengrui Medicine Co., Ltd. Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof
WO2010114943A1 (en) * 2009-04-01 2010-10-07 Pliva Hrvatska D.O.O. Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof
WO2014177517A1 (en) * 2013-04-29 2014-11-06 Esteve Química, S.A. Preparation process of an agonist of the thrombopoietin receptor

Also Published As

Publication number Publication date
WO2015111085A2 (en) 2015-07-30
WO2015111085A8 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
EP3402787A4 (en) Processes for the preparation of 2,5-furandicarboxylic acid and intermediates and derivatives thereof
WO2016011390A8 (en) Irak4 inhibiting agents
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
EP3828186A3 (en) Pyrimidinones as factor xia inhibitors
WO2015200680A3 (en) Prmt5 inhibitors and uses thereof
MA39749A (en) Piperidine-dione derivatives
WO2016079751A3 (en) A process for preparation of vortioxetine and polymorphs thereof
WO2015110897A3 (en) Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
MX2021008002A (en) Novel salts and polymorphic form of bempedoic acid.
MA39956A (en) Benzomorphan analogs and use thereof
WO2015171526A3 (en) Tricyclic pyrazolopyridine compounds
WO2017042828A3 (en) Process for the preparation of selexipag
WO2016089060A3 (en) Heterocyclic derivatives and use thereof
WO2015142903A3 (en) Method of controlling lactate production with piperdine-dione derivatives
EP3480198A4 (en) Novel compound or pharmaceutically acceptable salt thereof
PH12016501252A1 (en) Novel tetrahydropyridopyrimidine compound or salt thereof
EP3497090A4 (en) Novel processes for preparation of dapagliflozin or its solvates or co-crystals thereof
WO2016013030A3 (en) Hydroxysteroid compounds, their intermediates, process of preparation, composition and uses thereof
WO2015121877A3 (en) Polymorphs of lomitapide and its salts
WO2016166720A3 (en) Polymorphs of afatinib and its salts and process for the preparation of quinazolinyl derivatives
WO2015111085A8 (en) Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
EP4249072A3 (en) Crystalline forms of quinolone analogs and their salts
WO2018125880A8 (en) Nrf2 activator
WO2015191681A3 (en) Substituted pyridinones as mgat2 inhibitors

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15721345

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 15721345

Country of ref document: EP

Kind code of ref document: A2